Muscle-Sparing GLP-1 Combinations: The Drugs Aiming to Preserve Lean Mass During Weight Loss

GLP-1 receptor agonists like semaglutide produce large, reliable reductions in body weight. But weight is not only fat. A recurring finding across trials is that some of the weight lost on GLP-1 therapy is lean mass — muscle and other non-fat tissue. That observation has opened a new research direction: pairing a GLP-1 drug with a second agent designed specifically to protect muscle. This is a research log entry on where that work stands in 2025–2026, and it is investigational throughout.

Why lean-mass loss is on the radar

When the body loses weight rapidly, it tends to shed both fat and lean tissue. The open question is how much, and whether it matters clinically over the long term. Two 2025 trial readouts put concrete numbers on the problem in the context of semaglutide.

In Regeneron's Phase 2 COURAGE trial, roughly 33% of the weight lost on semaglutide alone was attributed to lean mass. In the Phase 2b BELIEVE trial presented at the 2025 American Diabetes Association Scientific Sessions (June 20–23, Chicago), semaglutide 2.4 mg was associated with about 7.4% lean mass loss. These are trial-specific measurements, not universal constants — the exact figure depends on the population, dose, imaging method, and duration — but both point in the same direction: a meaningful fraction of GLP-1 weight loss is not fat.

Whether preserving that lean mass improves hard outcomes (strength, function, metabolic health, weight-regain resistance) is still being studied. The drugs below are being tested against that hypothesis, not proven against it.

Bimagrumab plus semaglutide: the BELIEVE trial

Bimagrumab is a first-in-class monoclonal antibody that targets activin type II receptors, a signaling pathway involved in muscle growth. By blocking those receptors, it is designed to promote muscle preservation and growth.

BELIEVE was a randomized, double-blind, placebo-controlled Phase 2b study in adults with overweight or obesity, testing bimagrumab alone and combined with semaglutide. The reported body-composition contrast was notable:

On fat-loss "quality," the combination drew 92.8% of total weight loss from fat mass, versus 71.8% for semaglutide alone, alongside a roughly 22.1% decrease in body weight. In other words, the combination shifted the composition of weight lost toward fat while still delivering large total reductions.

Trevogrumab (anti-myostatin) plus semaglutide: the COURAGE trial

Regeneron's approach targets myostatin, a natural brake on muscle growth. Trevogrumab is an anti-GDF8/anti-myostatin antibody. The Phase 2 COURAGE trial paired semaglutide with trevogrumab, with or without garetosmab (an anti-activin A antibody), in obesity.

Interim results reported that adding trevogrumab prevented roughly half of the lean-mass loss seen with semaglutide alone, with the combination preserving on the order of 50%–80% of lean mass relative to semaglutide monotherapy. Adding garetosmab on top — a triple combination — enhanced fat reduction by about 27.3% over semaglutide alone while preserving more than 80% of lean body mass.

Safety is where the nuance sharpens. Discontinuation due to adverse events was about 4.6% for semaglutide alone, 4.7% for semaglutide plus trevogrumab 200 mg, 10.6% for the 400 mg trevogrumab pairing, and 30.9% for the triple combination. Muscle spasm was the most commonly reported side effect. That gradient is a reminder that stacking mechanisms can raise the tolerability cost, and the triple combo's discontinuation rate is high. COURAGE is expected to complete in late 2026, with maintenance-phase data (weeks 26–52) still to come.

How myostatin/activin blockade relates to peptides

The muscle-preservation logic here overlaps conceptually with molecules discussed elsewhere in the research literature. Follistatin, for example, is a natural antagonist of myostatin and activin — the same broad pathway bimagrumab, trevogrumab, and garetosmab act on, albeit through different molecular tools (antibodies versus a binding protein). Understanding the myostatin/activin axis helps explain why several independent programs converged on it as the lever for sparing muscle during weight loss.

What is — and is not — established

Everything above is Phase 2 or Phase 2b data. These are dose-finding, proof-of-mechanism studies, not confirmatory Phase 3 outcomes, and not evidence of long-term functional or clinical benefit. None of these combinations is an approved muscle-sparing weight-loss regimen. Bimagrumab, trevogrumab, and garetosmab are investigational agents in this setting; you can check general regulatory context on our FDA status reference, and you should always verify current approval status against primary sources.

The honest summary for 2025–2026: multiple credible programs have shown, in mid-stage trials, that co-administering a myostatin/activin-pathway antibody with semaglutide can shift weight loss toward fat and blunt lean-mass loss. Whether that translates into approved therapies, and into outcomes patients feel, depends on Phase 3 results and longer follow-up that do not yet exist.

PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.